This research study has been ongoing for 10 years and originally funded by the American Cancer Society. For the past 3 years it has been funded by the National Cancer institute but with a different focus. The three goals of this study are:
To improve the accuracy of screening tests for the diagnosis of prostate cancer.
Identify biomarkers that will predict how aggressive prostate cancer will be. The tests currently in use for screening for prostate cancer are the PSA blood test and digital rectal examination (DRE) of the prostate. When either or both of these tests are positive, a tissue biopsy of the prostate is recommended.
The third goal is to provide accurate information about how rapidly prostate cancers will become worse. To accomplish this we will study tissue and blood to identify proteins and genes that are present at high or low levels in prostate cancers that progress slowly versus those that progress more rapidly.
The purpose of this study is determine which type of anti-hormonal therapy and radiation therapy will result in an improvement in survival in patients with “unfavorable” intermediate risk or “favorable” high risk prostate cancer. The risk is the possibility or chances of the prostate cancer coming back after being treated.
The primary objective is to see which treatment improves the duration of survival. The study will enroll 2,580 participants from many cancer centers in the US.
In addition to other conditions for enrollment, men who were diagnosed with prostate cancer within the past 180 days and have no evidence of lymph node involvement by CT scan or MRI within the past 90 days may be enrolled. Men are not eligible for this study if the prostate or testes have been surgically removed. Men who have already been treated with brachytherapy or radiation to the pelvis or hormonal therapy are not enrolled. Patients with a history of other cancers may not be eligible.
Utilize biomarkers and imaging to identify men who have prostate cancer but low PSA levels.